 phase trial high-dose diaziquone autologous bone marrow transplantation Illinois Cancer Council study Diaziquone AZQ synthetic quinone demonstrated activity acute nonlymphocytic leukemia ANLL primary CNS tumors non-Hodgkin lymphoma NHL devoid nonhematopoietic toxicity conventional doses prelude inclusion bone marrow transplant BMT preparative regimens phase high-dose AZQ autologous BMT ABMT Patients refractory solid tumors lymphomas single infusion AZQ dose escalations Fifty-six patients courses granulocyte platelet counts Nausea stomatitis diarrhea mild transient dose-related Transient minimal elevations liver function tests patients dose-related dose MTD high-dose AZQ nephrotoxicity dose-limiting Significant azotemia patients fatal anuric renal failure patients Reversible proteinuria courses nephrotic range proteinuria courses doses proteinuria multiple proximal tubular defects aminoaciduria proximal renal tubular acidosis early deaths early renal failure sepsis pulmonary embolus progressive disease patients assessable response responses primary CNS tumors malignant melanoma non-small-cell lung carcinoma breast carcinoma ovarian carcinoma activity ANLL NHL unique toxicity spectrum high-dose AZQ efficacy current BMT preparative regimens nonhematopoietic toxicity